Skip to content
Clinical Trials – home
Not yet recruiting

Phase 1b/2 Study of Patritumab Deruxtecan and Trastuzumab Deruxtecan in Hormone Receptor‑Positive, HER2‑Low/Ultralow Unresectable or Metastatic Breast Cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study looks at people with Hormone Receptor Positive, HER2‑low or HER2‑ultralow, unresectable or metastatic breast cancer. “Hormone receptor positive” means the cancer cells grow in response to hormones, “HER2‑low” or “HER2‑ultralow” describes a small amount of a protein on the cells, “unresectable” means the tumor cannot be removed by surgery, and “metastatic” means the cancer has spread to other parts of the body. Participants receive two medicines given by intravenous infusion (the drug is slowly delivered into a vein). The two drugs are Patritumab deruxtecan (also called HER3‑DXd) and Trastuzumab deruxtecan (also called T‑DXd), which are designed to target specific proteins on the cancer cells.

The purpose of the study is to evaluate the safety, tolerability and anti‑tumor activity of the two medicines when used together. After an initial screening, participants receive the infusions on a regular schedule and attend clinic visits for routine checks such as blood tests, heart scans, eye exams, and imaging scans to see whether the tumors shrink. The study follows participants for several months, recording any side effects and measuring how the cancer responds over time.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Evaluation

    After joining the study, you will undergo a series of initial tests to record your health status before any treatment is given.

    These tests include a physical examination, measurement of vital signs such as blood pressure and pulse, an ECG (a simple heart rhythm test), an assessment of LVEF (how well the heart pumps blood), standard laboratory blood work, an eye examination, and imaging scans to document the size and location of any tumors.

  2. Step 2

    First Treatment Administration

    You will receive two study medicines, patritumab deruxtecan and trastuzumab deruxtecan, each given as an intravenous infusion (a medication delivered through a vein).

    The exact dose, how often the infusion is given, and the total length of treatment are determined by the study protocol and are not specified in the available information.

  3. Step 3

    Repeated Treatment Cycles

    The infusions of patritumab deruxtecan and trastuzumab deruxtecan will be repeated in subsequent treatment cycles according to the schedule set by the study.

    Each cycle includes the same infusion process as the first treatment.

  4. Step 4

    Safety Monitoring During Each Cycle

    Before and after every infusion you will be checked for any new or worsening side effects, including serious events that require medical attention.

    Monitoring includes another ECG, a repeat assessment of LVEF, vital sign measurements, laboratory blood tests, and an eye exam to detect any changes.

  5. Step 5

    Tumor Response Assessment

    At intervals defined by the study, imaging scans will be performed to evaluate how the tumors are responding to the treatment.

    The scans are interpreted using RECIST v1.1, a standard method that measures changes in tumor size to determine whether the disease is shrinking, stable, or progressing.

  6. Step 6

    End of Treatment

    Treatment will stop if the disease gets worse, if side effects become unacceptable, or if the study reaches its predefined end point.

    The decision to end treatment is made by the clinical team based on the safety and tumor assessment results.

  7. Step 7

    Follow‑Up Visits

    After treatment ends, you will continue to have regular follow‑up visits to monitor long‑term safety and overall survival.

    These visits may include physical examinations, laboratory tests, and imaging studies performed at intervals specified by the study protocol.

Who can join the trial?

14 criteria

  • Sign and date the Informed Consent Form before any study procedures begin; this form explains the study and your rights.
  • Be at least 18 years old on the day you sign the consent form.
  • Have breast cancer that has been confirmed by a tissue test (pathology) as defined in the study.
  • Provide a pretreatment tumor tissue sample that meets the study’s requirements; this is a small piece of tumor taken before starting the study drug.
  • Show cancer that has gotten worse on scans (called radiologic progression) according to the study’s criteria.
  • Have already been treated with a CDK4/6 inhibitor, a type of medicine that blocks certain proteins that help cancer grow.
  • If you have specific gene changes (such as PIK3CA, PTEN, AKT, or BRCA1/2) and are eligible for targeted therapy, you must have received that therapy before entering the study unless it is not possible.
  • Not have received chemotherapy for unresectable or metastatic breast cancer; chemotherapy given before surgery (neoadjuvant) or after surgery (adjuvant) is allowed.
  • Have an ECOG performance status of 0 or 1 at screening; this scale measures how well you can carry out daily activities, where 0 means fully active and 1 means limited in strenuous activity but still able to walk.
  • Have at least one measurable lesion seen on a CT (computed tomography) or MRI (magnetic resonance imaging) scan, as defined by the RECIST v1.1 criteria.
  • Show adequate bone marrow reserve and organ function based on lab tests done within 7 days before the first dose.
  • If you are a woman who could become pregnant (childbearing potential), you must follow the study’s birth‑control requirements.
  • If you are a man who can produce sperm, you must agree to use contraception during the study and for 4 months after the last dose.
  • Be willing and able to attend scheduled visits, take the study drug as planned, have laboratory tests, and follow any study restrictions.

Who cannot join the trial?

20 criteria

  • You have already received a medication that targets HER3 (an anti‑HER3 antibody) or a drug that combines an antibody with a chemotherapy agent called a topoisomerase I inhibitor (such as T‑Dx d).
  • You received any other cancer‑treating medicine, including experimental drugs, within the last 4 weeks (or less than five times the drug’s half‑life, whichever is shorter).
  • You did not have enough time for the previous medicines to leave your body (the required “washout period”) before starting this study.
  • You have uncontrolled or serious heart or blood‑vessel problems, as defined by the study doctors.
  • You have an active or uncontrolled hepatitis B infection (a liver virus). Testing for hepatitis B is required.
  • You have an active or uncontrolled hepatitis C infection (another liver virus). Testing for hepatitis C is required.
  • You have an active or uncontrolled HIV infection (the virus that causes AIDS). Testing for HIV is required.
  • You have had another active cancer within the past 3 years, except for cancers specifically allowed by the study.
  • You still have side effects from previous cancer treatment that have not resolved to a mild level (grade 1 or less) according to standard toxicity grading (NCI‑CTCAE v5.0), except for hair loss.
  • You are allergic or have any known reaction to the study drugs or any of their inactive ingredients.
  • You have a current uncontrolled infection caused by bacteria, fungi, or viruses throughout your body (localized skin or nail fungal infections are allowed).
  • You have ever had interstitial lung disease (ILD) or pneumonitis (lung inflammation), or you currently have or suspect these conditions, even if you are taking steroids.
  • You have very severe breathing problems caused by other lung illnesses, as judged by the doctor.
  • You are taking high‑dose oral steroids (more than 10 mg of prednisone daily or an equivalent) or other strong immune‑suppressing medicines on a long‑term basis.
  • You have evidence of leptomeningeal disease (cancer spread to the membranes covering the brain and spinal cord).
  • You have active spinal cord compression or brain metastases that are causing symptoms or need treatment with steroids or seizure medicines. (Patients with treated, symptom‑free brain metastases may be allowed if stable for at least 4 weeks.)
  • You have significant corneal disease (serious problems with the clear front part of the eye).
  • You have any severe or uncontrolled systemic illness (such as active bleeding problems, serious infection), major psychiatric issues, substance abuse, or other factors that the doctor believes would make participation unsafe or unreliable.
  • You have any other medical condition, past surgery, physical finding, or lab result that the doctor thinks could affect your safety, change how the drug works in your body, or make the study results difficult to interpret.
  • Personal, social, family, or geographic circumstances that would prevent you from attending regular follow‑up visits.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Patritumab deruxtecan

    is a medicine that combines a laboratory-made antibody with a chemotherapy drug. The antibody part is designed to find and attach to a protein called HER3 that is often found on breast cancer cells. Once it binds, the attached chemotherapy is released directly into the cancer cell, helping to kill it while trying to limit damage to normal cells. In this study, patritumab deruxtecan is being given together with another drug to see how safe it is, how well patients can tolerate it, and whether it helps shrink or stop the growth of breast tumors that have low levels of HER2.

  • Trastuzumab deruxtecan

    is another medicine that links an antibody to a chemotherapy agent. Its antibody is made to target a protein called HER2, which can be present in small amounts on some breast cancer cells. By attaching to HER2, the drug delivers the chemotherapy straight to the cancer cells, aiming to destroy them while sparing healthy tissue. In this trial, trastuzumab deruxtecan is used together with patritumab deruxtecan to evaluate its safety, how well patients tolerate it, and its ability to fight tumors in people with hormone‑receptor‑positive, HER2‑low or HER2‑ultralow breast cancer that cannot be removed by surgery or has spread.

What is already known about the treatment

  • Patritumab deruxtecan

    This medication is given by intravenous infusion as a clear solution prepared for infusion. It is currently an investigational drug being studied in clinical trials and has not yet received regulatory approval. It is being tested for use in hormone‑receptor‑positive, HER3‑expressing breast cancers that are HER2‑low or HER2‑ultralow and cannot be removed by surgery. The drug works by attaching an antibody that seeks out the HER3 protein on cancer cells and then releases a chemotherapy payload that stops DNA replication, classifying it as an HER3‑directed antibody‑drug conjugate.

  • Trastuzumab deruxtecan

    This medication is also administered as an intravenous infusion of a solution for infusion. It is an approved therapy in many countries for HER2‑positive metastatic breast cancer and is now being studied in HER2‑low breast cancer. It targets the HER2 protein on cancer cells and delivers a topoisomerase I inhibitor that interferes with DNA replication, leading to cancer cell death. It belongs to the class of HER2‑directed antibody‑drug conjugates.

Investigated diseases

Hormone receptor‑positive HER2‑low or HER2‑ultralow unresectable or metastatic breast cancer - This disease is a form of breast cancer that expresses estrogen or progesterone receptors but has low levels of the HER2 protein. The cancer cannot be removed surgically and has spread beyond the breast to other parts of the body, or is at a stage where surgery is not feasible. Over time the tumor may continue to grow and form new lesions in distant organs such as bone, liver, or lungs. The disease can evolve as cancer cells multiply and invade surrounding tissues. Symptoms may develop as the tumor burden increases, reflecting the ongoing progression of the disease.
Trial detailsLast updated 22 Nov 2026
Age18+ yearsPhasePhase ITrial ID2024-517541-14-00Protocol codeU31402-287Estimated enrolment220 patientsSponsorDaiichi Sankyo Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.